The other 2 subtypes confer bad prognosis, which contain the HER2 overexpressing breast cancer (ER−, PR−, and HER2+) and the triple-negative breast cancer (ER−, PR−, and HER−) [4]. This evidence concerns the gene ERBB2 and breast carcinoma.